Geron Corp GERN Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125

00:38 EDT 8 Oct 2019 | BioPortfolio Reports

Geron Corp GERN Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Geron Corp Geron is a latestage clinical biopharmaceutical company that focuses on developing and commercialization of imetelstat, a firstinclass telomerase inhibitor in hematologic myeloid malignancies. Imetelstat received Fast Track designation from the US FDA to treat patients with transfusiondependent anemia due to lower or intermediate risk myelodysplastic syndromes MDS who are nondel 5q and are resistant to an erythroid stimulating agent. The company utilizes core expertise in telomerase and telomere biology and its proprietary nucleic acid chemistry for the development of imetelstat. Geron primarily operates in the US and has collaboration with Paraxel to support for the development, manufacturing and commercialization of imetelstat. Geron is headquartered in Menlo Park, California, the US.

Geron Corp Key Recent Developments

Aug 01,2019: Geron reports second quarter 2019 financial results and recent events

Jun 20,2019: Geron appoints Vice President, Human Resources

May 16,2019: Geron Continues to Build Senior Leadership of Its Development Team

May 02,2019: Geron Corporation reports first quarter 2019 financial results

Mar 07,2019: Geron reports fourth quarter and full year 2018 financial results and recent events

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Geron Corp GERN Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125


More From BioPortfolio on "Geron Corp GERN Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125"

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...